metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	pembrolizumab plus lenvatinib
	KEYNOTE-581/CLEAR (PDL1), 2021 N Engl J Med 2021 Apr 8;384(14):1289-1300. NCT02811861	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	lenvatinib plus pembrolizumab	sunitinib	first-line treatment of patients with previously untreated advanced renal cell carcinoma with a clear-cell component	355 / 357	some concern	conclusif	demonstrated 34 % decrease in deaths (OS) (PE) demonstrated 61 % decrease in progression or deaths (PFS) (PE) demonstrated 97 % increase in objective responses (ORR) (PE) The combination of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) significantly improved progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) compared with sunitinib (Sutent)